Analysis of survival differences in advanced triple-negative breast cancer: a real-world study
In patients with aTNBC, those with dnMBC demonstrate a more pronounced survival benefit, with this advantage being consistent across various clinicopathological parameters. Therefore, stratifying patients by metastatic category in clinical trials may improve evaluation of treatment efficacy and support more individualized patient management.
Authors
- Pengfei Qiu (ORCID: https://orcid.org/0000-0001-6784-410X)
- Zhiqiang Shi (ORCID: https://orcid.org/0000-0002-8223-2766)
- Zhao Bi (ORCID: https://orcid.org/0000-0001-9546-1704)
- Yongsheng Wang (ORCID: https://orcid.org/0000-0003-3673-8376)
- Xiaowen Wang (ORCID: https://orcid.org/0000-0003-4623-1608)
- Junsheng Zheng
Institutions
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fonc.2025.1635243
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China